StockData

iBio vs Shattuck Labs

IBIO and STTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IBIO and STTK compare

Shattuck Labs is the larger company, worth 9.6 times as much as iBio ($507M against $53.0M).

iBio grew revenue faster over the last twelve months (115% versus −100% for Shattuck Labs).

iBio scores higher on the StockData Score (9 against 8 for Shattuck Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIBIOSTTK
Size and price
Market cap$53.0M$507M
Share price$0.824$5.05
Change, 1 year−36.1%167%
Change, 5 years−99.8%−46.3%
Beta (5Y)1.141.63
Employees2340
StockData Score
Total score9 (better)8
Valuation score1 (better)0
Growth score11
Performance score2 (better)1
Health score56 (better)
Dividend score00
Valuation
P/S49.3×–
P/B0.7× (better)2.6×
FCF yield−52.1%–
Growth
Revenue growth (TTM)115% (better)−100%
Revenue growth, 5Y average−46.9%−36.8% (better)
Profitability
Operating margin−3491%–
Net margin−3244%–
FCF margin−2566%–
Return on equity−51.8%−47.2% (better)
Return on invested capital−728% (better)−2531%
Financial health
Debt / equity0.000.00
Current ratio9.4815.80 (better)
Altman Z-score−3.1317.92 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield–−19.9%
Shareholder yield0.00% (better)−19.9%
Ownership
Held by institutions54.0%83.5%
Held by insiders0.47%24.1%
Insider net buying, 12 months$98.1K (better)−$342K
Short interest, % of float6.3%14.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.